Identification of hsa_circ_0002024 as a prognostic competing endogenous RNA (ceRNA) through the hsa_miR_129-5p/Anti-Silencing Function 1B Histone Chaperone (ASF1B) axis in renal cell carcinoma

References

• Wild CPWE, Stewart BW. World cancer report: cancer research for cancer prevention international agency for research on cancer. Lyon, France; 2020.
   Google Scholar
• Prasad SR, Humphrey PA, Catena JR, et al. Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. Radiographics. 2006;26:1795–1806.
   PubMed Web of Science ®Google Scholar
• Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis. 2014;21:81–90.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wu T, Simon J, et al. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science. 2018;361:290–295.
   PubMed Web of Science ®Google Scholar
• Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.
   PubMed Web of Science ®Google Scholar
• Znaor A, Lortet-Tieulent J, Laversanne M, et al. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67:519–530.
   PubMed Web of Science ®Google Scholar
• Cella D, Grünwald V, Nathan P, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol 2016 994–1003. doi :10.1016/S1470-2045(16)30125-5
   PubMedGoogle Scholar
• Wang Y-Q, Wu Y, et al. A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls. Oncogenesis. 2016;5:e192–e192.
   PubMed Web of Science ®Google Scholar
• Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10:967–974.
   PubMed Web of Science ®Google Scholar
• Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the rosetta stone of a hidden RNA language? Cell. 2011;146(3):353–358.
   PubMed Web of Science ®Google Scholar
• Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov. 2013;3:1113–1121.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liang W, Zhang P, et al. Circular RNAs: emerging cancer biomarkers and targets. J Exp Clin Cancer Res. 2017;36:152.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Du Y, Yang X, et al. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol Cancer. 2018;17:79.
   PubMed Web of Science ®Google Scholar
• Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333–338.
   PubMed Web of Science ®Google Scholar
• Jin J, Sun H, Shi C, et al. Circular RNA in renal diseases. J Cell Mol Med. 2020;24:6523–6533.
   PubMed Web of Science ®Google Scholar
• Wan J, Liu B. Construction of lncRNA-related ceRNA regulatory network in diabetic subdermal endothelial cells. Bioengineered. 2021;12:2592–2602.
   Web of Science ®Google Scholar
• Zhang X, Cui Y, Ding X, et al. Analysis of mRNA-lncRNA and mRNA-lncRNA-Pathway co-expression networks based on WGCNA in developing pediatric sepsis. Bioengineered. 2021;12(1):1457-1470.
   Web of Science ®Google Scholar
• Mat AR, Masli AB, Burhan NH, et al. SRA tool: SOFL-based requirements analysis tool. Adv Intell Syst Comput. 2013;209:217–226.
   Google Scholar
• Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Genomics. 2013;1303.
   Google Scholar
• Gao Y, Wang J, Zhao F. CIRI: an efficient and unbiased algorithm for de novo circular RNA identification. Genome Biol. 2015;16:4.
   PubMed Web of Science ®Google Scholar
• Team RC. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Journal 2020.
   Google Scholar
• Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44:e71.
   PubMed Web of Science ®Google Scholar
• Robinson MD, McCarthy DJ and Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–140.
   PubMed Web of Science ®Google Scholar
• Villanueva, Randle A, Chen, et al. ggplot2: Elegant Graphics for Data Analysis (2nd ed.). Measurement: Interdisciplinary Research and Perspectives. 2019;17: 160–167.
   Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.
   PubMed Web of Science ®Google Scholar
• Gene OC, Mulder N. The Gene Ontology (GO) project in 2006. Nucleic Acids Res. 2005;34:D322-D326.
   Web of Science ®Google Scholar
• Minoru K, Susumu G. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000;28:27-30.
   Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284–287.
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–2504.
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (New York, NY). 2004;6:1–6.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98-W102.
   Web of Science ®Google Scholar
• Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000.
   Google Scholar
• Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010;10:389–402.
   PubMed Web of Science ®Google Scholar
• Saikat D, Niloy B. microRNA: a new generation therapeutic target in diabetic nephropathy. Biochem Pharmacol. 2018;155:32-47.
   Web of Science ®Google Scholar
• Cui X, Wang J, Guo Z, et al. Emerging function and potential diagnostic value of circular RNAs in cancer. Mol Cancer. 2018;17:123.
   PubMed Web of Science ®Google Scholar
• Jeck WR, Sorrentino JA, Wang K, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19:141–157.
   PubMed Web of Science ®Google Scholar
• Vo JN, Cieslik M, Zhang Y, et al. The landscape of circular RNA in cancer. Cell. 2019 e813;176:869–881.
   PubMed Web of Science ®Google Scholar
• Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505:344–352.
   PubMed Web of Science ®Google Scholar
• Qi X, Zhang DH, Wu N, et al. ceRNA in cancer: possible functions and clinical implications. J Med Genet. 2015;52(10):710-718.
   Web of Science ®Google Scholar
• Zhang S, Zhu D, Li H, et al. Characterization of circRNA-associated-ceRNA networks in a senescence-accelerated mouse prone 8 brain. Molecular Therapy. 2017;25:2053–2061.
   Web of Science ®Google Scholar
• Zheng Q, Bao C, Guo W, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun. 2016;7:11215.
   PubMed Web of Science ®Google Scholar
• Wang Y, Dong D, Jiang S, et al. miR-216b post-transcriptionally downregulates oncogene KRAS and inhibits cell proliferation and invasion in clear cell renal cell carcinoma. Cell Physiol Biochem. 2018;49:1755–1765.
   PubMedGoogle Scholar
• Wei X, Yu L, Kong X. miR-488 inhibits cell growth and metastasis in renal cell carcinoma by targeting HMGN5. Onco Targets Ther. 2018;11:2205–2216.
   PubMed Web of Science ®Google Scholar
• Pan Y, Hu J, et al. MiR‐193a‐3p and miR‐224 mediate renal cell carcinoma progression by targeting alpha‐2,3‐sialyltransferase IV and the phosphatidylinositol 3 kinase/Akt pathway. Mol Carcinog. 2018;57:1067–1077.
   Web of Science ®Google Scholar
• Chen L, Wu D, Ding T. Circular RNA circ_0001368 inhibited growth and invasion in renal cell carcinoma by sponging miR-492 and targeting LATS2. Gene. 2020;753:144781.
   PubMed Web of Science ®Google Scholar
• Jin C, Shi L, Li Z, et al. Circ_0039569 promotes renal cell carcinoma growth and metastasis by regulating miR-34a-5p/CCL22. Am J Transl Res. 2019;11:4935–4945.
   PubMed Web of Science ®Google Scholar
• Li R, Luo S, Zhang D. Circular RNA hsa_circ_0054537 sponges miR-130a-3p to promote the progression of renal cell carcinoma through regulating cMet pathway. Gene. 2020;754:144811.
   PubMed Web of Science ®Google Scholar
• Gatchalian J, Malik S, Ho J, et al. A non-canonical BRD9-containing BAF chromatin remodeling complex regulates naive pluripotency in mouse embryonic stem cells. Nat Commun. 2018;9(1): 5139.
   Web of Science ®Google Scholar
• Huang M, Wang H. lncRNA MALAT1 binds chromatin remodeling subunit BRG1 to epigenetically promote inflammation-related hepatocellular carcinoma progression. Oncoimmunology. 2019;8:e1518628.
   PubMed Web of Science ®Google Scholar
• Jiangqiao Z, Tao Q, Zhongbao C, et al. Anti-silencing function 1B histone chaperone promotes cell proliferation and migration via activation of the AKT pathway in clear cell renal cell carcinoma. Biochem Biophys Res Commun. 2019;511:165–172.
   PubMed Web of Science ®Google Scholar
• Corpet A, De Koning L, Toedling J, et al. Asf1b, the necessary ASF1 isoform for proliferation, is predictive of outcome in breast cancer. EMBO J. 2011;30:480–493.
   PubMed Web of Science ®Google Scholar
• Meng R, Fang J, Yu Y, et al. miR-129-5p suppresses breast cancer proliferation by targeting CBX4. Neoplasma. 2018;65:572–578.
   PubMed Web of Science ®Google Scholar
• Han G, Zhang X, Liu P, et al. Knockdown of anti-silencing function 1B histone chaperone induces cell apoptosis via repressing PI3K/Akt pathway in prostate cancer. Int J Oncol. 2018;53:2056–2066.
   PubMed Web of Science ®Google Scholar
• Gentilucci A, Valentino A, Calarco A, et al. Deregulation of microRNAs mediated control of carnitine cycle in prostate cancer: molecular basis and pathophysiological consequences. Eur Urol Suppl. 2018;17:168–169.
   Google Scholar
• Chiang K-C, Lai C-Y, Chiou H-L, et al. Timosaponin AIII inhibits metastasis of renal carcinoma cells through suppressing cathepsin C expression by AKT/miR-129-5p axis. J Cell Physiol. 2019;234(8):13332–13341.
   PubMed Web of Science ®Google Scholar
• Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol Biosyst. 2015;11:1946–1954.
   PubMedGoogle Scholar
• Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med. 2015;67:11.
   PubMed Web of Science ®Google Scholar